Gaibar, M.; Galán, M.; Romero-Lorca, A.; Antón, B.; Malón, D.; Moreno, A.; Fernández-Santander, A.; Novillo, A.
Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer. Int. J. Mol. Sci. 2021, 22, 1381.
https://doi.org/10.3390/ijms22031381
AMA Style
Gaibar M, Galán M, Romero-Lorca A, Antón B, Malón D, Moreno A, Fernández-Santander A, Novillo A.
Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences. 2021; 22(3):1381.
https://doi.org/10.3390/ijms22031381
Chicago/Turabian Style
Gaibar, MarÃa, Miguel Galán, Alicia Romero-Lorca, Beatriz Antón, Diego Malón, Amalia Moreno, Ana Fernández-Santander, and Apolonia Novillo.
2021. "Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer" International Journal of Molecular Sciences 22, no. 3: 1381.
https://doi.org/10.3390/ijms22031381
APA Style
Gaibar, M., Galán, M., Romero-Lorca, A., Antón, B., Malón, D., Moreno, A., Fernández-Santander, A., & Novillo, A.
(2021). Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 22(3), 1381.
https://doi.org/10.3390/ijms22031381